Last reviewed 2026-04-19 · How we verify

SH1573 Capsules

Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 1 active Small molecule

SH1573 Capsules is a Small molecule drug developed by Nanjing Sanhome Pharmaceutical, Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic name	SH1573 Capsules
Sponsor	Nanjing Sanhome Pharmaceutical, Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SH1573 Capsules CI brief — competitive landscape report
SH1573 Capsules updates RSS · CI watch RSS
Nanjing Sanhome Pharmaceutical, Co., Ltd. portfolio CI

Frequently asked questions about SH1573 Capsules

What is SH1573 Capsules?

SH1573 Capsules is a Small molecule drug developed by Nanjing Sanhome Pharmaceutical, Co., Ltd..

Who makes SH1573 Capsules?

SH1573 Capsules is developed by Nanjing Sanhome Pharmaceutical, Co., Ltd. (see full Nanjing Sanhome Pharmaceutical, Co., Ltd. pipeline at /company/nanjing-sanhome-pharmaceutical-co-ltd).

What development phase is SH1573 Capsules in?

SH1573 Capsules is in Phase 1.

Manufacturer: Nanjing Sanhome Pharmaceutical, Co., Ltd. — full pipeline
Compare: SH1573 Capsules vs similar drugs
Pricing: SH1573 Capsules cost, discount & access